All In Biotech

Drug Trial Radar · NCT04372108

A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

An Observational Study to Assess the Long-term Safety of Ustekinumab Versus Other Biologic Therapies Among Patients With Crohn's Disease and Ulcerative Colitis: A New-User Cohort Study Using the Department of Defense Electronic Health Records Database

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,536

Planned (sponsor's estimate)

Start

Jun 24, 2021

Primary completion

Aug 31, 2029

Study completion Aug 30, 2030

Sponsor

Lead sponsor
Janssen Scientific Affairs, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
May 1, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).

Conditions

  • Crohn Disease
  • Colitis, Ulcerative

Interventions

  • UstekinumabDrug

    Participants who are new users of ustekunumab will be included in the cohort. No study treatment will be administered as a part of this study.

  • Other Biologic TherapiesDrug

    Participants who are new users of other biologic therapies (for examples for example, infliximab, adalimumab, or vedolizumab administered as per the prescription record) will be included in this cohort. No study treatment will be administered as a part of this study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Rate for MalignancyTime frame: Up to 10 years and 3 months
  2. Time from Treatment Initiation to First Diagnosed MalignancyTime frame: Up to 10 years and 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • BAMC

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.